Jon Ellis and Simon Vanstone, PhD, go behind the headlines to explore the latest M&A activity and what tariffs and funding changes could mean for mRNA and beyond.

DIA, a global non-profit organization of life sciences professionals, will induct four Fellows of DIA and recognize six recipients of Global Inspire Awards and America's Inspire Awards on June 15 as ...

Eli Lilly joins up with Camurus to make long-acting versions of the pharma's obesity and diabetes drugs, joining the industry ...

Although as of this week the stock has declined by more than 4% since the start of the year, there's little reason to believe ...

The deal, which could be worth up to $870 million overall, will give Lilly access to a delivery technology that may help ...

As Merck & Co., Bristol Myers Squibb and Pfizer have hopped on the PD-(L)1xVEGF bispecific bandwagon, the question becomes ...

Camurus (OTC:CAMRF) and Eli Lilly and Company (NYSE:LLY) entered into a collaboration and license agreement. This agreement grants Lilly exclusive, worldwide rights to research, develop, manufacture, ...